Levallorphan
Lorfan (levallorphan) is a small molecule pharmaceutical. Levallorphan was first approved as Lorfan on 1982-01-01. The pharmaceutical is active against mu-type opioid receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levallorphan tartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LORFAN | Roche | N-010423 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
373 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 10 | 36 | 62 | 46 | 28 | 182 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 3 | 6 | 22 | 21 | 20 | 72 |
| Healthy volunteers/patients | — | 8 | 1 | — | 1 | 5 | 15 | ||
| Exercise-induced asthma | D001250 | J45.990 | — | — | 3 | 2 | — | 5 | |
| Status asthmaticus | D013224 | 2 | 1 | — | 2 | — | 5 | ||
| Disease progression | D018450 | — | — | — | 2 | 1 | 3 | ||
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | — | 1 | 1 | 3 | |
| Hyperkalemia | D006947 | HP_0002153 | E87.5 | — | — | — | 2 | 1 | 3 |
| Pediatric obesity | D063766 | — | — | — | 2 | 1 | 3 | ||
| Airway obstruction | D000402 | — | — | — | 1 | 2 | 3 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 1 | — | 1 | — | 2 | 4 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | 3 | — | — | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 2 | — | 1 | 3 |
| Bronchial spasm | D001986 | — | 2 | 1 | — | — | 3 | ||
| Conjunctivitis | D003231 | H10 | — | — | 2 | — | — | 2 | |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | — | 2 | — | — | 2 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | 1 | 1 | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | 1 | ||
| Familial dysautonomia | D004402 | Orphanet_1764 | G90.1 | — | — | 1 | — | — | 1 |
| Organophosphate poisoning | D062025 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bronchiolitis | D001988 | HP_0011950 | 1 | 1 | — | — | 1 | 3 | |
| Cough | D003371 | HP_0012735 | R05 | — | 1 | — | — | 1 | 2 |
| Discoid lupus erythematosus | D008179 | L93.0 | — | 2 | — | — | — | 2 | |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | 1 | — | — | — | 1 |
| Familial primary pulmonary hypertension | D065627 | I27.0 | — | 1 | — | — | — | 1 | |
| Lymphangioleiomyomatosis | D018192 | J84.81 | 1 | 1 | — | — | — | 1 | |
| Viral bronchiolitis | D001990 | — | 1 | — | — | — | 1 | ||
| Brain death | D001926 | G93.82 | — | 1 | — | — | — | 1 | |
| Pulmonary edema | D011654 | EFO_1001134 | J81 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | — | — | — | — | 2 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | 1 | — | — | — | — | 1 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | 1 | — | — | — | — | 1 | |
| Congenital myasthenic syndromes | D020294 | Orphanet_590 | G70.2 | 1 | — | — | — | — | 1 |
| Ciliary motility disorders | D002925 | EFO_0003900 | 1 | — | — | — | — | 1 | |
| Transient tachypnea of the newborn | D059245 | P22.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 4 | 4 |
| Smoking | D012907 | EFO_0003768 | F17 | — | — | — | — | 3 | 3 |
| Airway remodeling | D056151 | — | — | — | — | 2 | 2 | ||
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | — | 1 | 1 |
| Viruses | D014780 | NCBITaxon_10239 | STY/T005 | — | — | — | — | 1 | 1 |
| Food hypersensitivity | D005512 | EFO_1001890 | — | — | — | — | 1 | 1 | |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Alpha 1-antitrypsin deficiency | D019896 | E88.01 | — | — | — | — | 1 | 1 | |
| Argininosuccinic aciduria | D056807 | — | — | — | — | 1 | 1 |
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LEVALLORPHAN |
| INN | levallorphan |
| Description | Levallorphan (INN, BAN) (brand names Lorfan, Naloxifan, Naloxiphan), also known as levallorphan tartrate (USAN), is an opioid modulator of the morphinan family used as an opioid analgesic and opioid antagonist/antidote. It acts as an antagonist of the μ-opioid receptor (MOR) and as an agonist of the κ-opioid receptor (KOR), and as a result, blocks the effects of stronger agents with greater intrinsic activity such as morphine whilst simultaneously producing analgesia.
|
| Classification | Small molecule |
| Drug class | narcotic antagonists/agonists (morphinan derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13 |
Identifiers
| PDB | — |
| CAS-ID | 152-02-3 |
| RxCUI | 6370 |
| ChEMBL ID | CHEMBL1254682 |
| ChEBI ID | 6431 |
| PubChem CID | 5359371 |
| DrugBank | DB00504 |
| UNII ID | 353613BU4U (ChemIDplus, GSRS) |
Target
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 377 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
45 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more